Pallando Therapeutics builds next‑generation targeted protein degraders that fuse high‑affinity binders with engineered E3 ligase recruitment tags to direct disease‑relevant proteins to the proteasome. Using computational design and structure‑guided optimization, its modular platform creates bifunctional molecules with sub‑nanomolar potency and selective degradation, enabling pharmaceutical and biotech partners to tackle previously undruggable targets with improved efficacy and safety.
Funding
$17M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AFounders
Product
Problem
Current therapeutic modalities often rely on inhibition rather than removal of disease-causing proteins, limiting efficacy and leading to off‑target effects. Existing protein‑degradation technologies lack precise targeting, resulting in suboptimal potency and safety profiles for many indications.
Solution
Pallando Therapeutics develops next‑generation targeted protein degraders that combine high‑affinity binding domains with engineered degradation tags to direct disease‑relevant proteins to the cellular proteasome. Their platform uses computational design and structure‑guided engineering to achieve precise spatial and temporal control over degradation, improving potency while minimizing collateral protein loss. By integrating proprietary ligand‑selection pipelines with optimized E3 ligase recruitment, the company delivers degraders that can address previously “undruggable” targets. The resulting therapeutics are intended to provide higher clinical efficacy and better safety margins compared with conventional inhibitors.
Target Audience
Primary customers are pharmaceutical and biotech companies seeking to develop novel therapeutics for targets that are difficult to inhibit with traditional small molecules.
Features
- Computationally designed bifunctional molecules that link target binders to selected E3 ligase recruiters
- Structure‑based optimization workflow to achieve sub‑nanomolar binding affinity and selective degradation
- Modular platform enabling rapid generation of degraders for diverse protein classes, including transcription factors and scaffolding proteins
- In‑cell validation suite with quantitative proteomics to confirm target knockdown and off‑target profiling
- Scalable synthesis and formulation processes compatible with oral and injectable delivery routes